Table 3 The univariate analysis for the OS and PFS.
OS | PFS | |||
|---|---|---|---|---|
χ2 | P value | χ2 | P value | |
Gender (female vs. male) | 0.244 | 0.621 | 0.046 | 0.831 |
Age, year (≤ 40 vs. > 40) | 3.331 | 0.068 | 0.516 | 0.472 |
ECOG-PS, score (0 vs. 1) | 0.010 | 0.921 | 0.175 | 0.676 |
Child–pugh (A vs. B) | 2.266 | 0.132 | 2.512 | 0.113 |
BCLC (B vs. C) | 6.886 | 0.009 | 2.206 | 0.137 |
Therapeutic regimen (control vs. experimental) | 5.116 | 0.024 | 6.362 | 0.012 |
Alcohol use (yes vs. no) | 0.689 | 0.406 | 0.633 | 0.426 |
Concomitant disease (yes vs. no) | 2.357 | 0.502 | 1.477 | 0.688 |
HBsAg (yes vs. no) | 0.194 | 0.659 | 0.136 | 0.712 |
HBV-DNA (negative vs. positive) | 0.161 | 0.688 | 0.469 | 0.493 |
Tumor differentiation(poorly vs. well and moderately) | 8.245 | 0.010 | 3.664 | 0.056 |
Extrahepatic metastasis (yes vs. no) | 6.648 | 0.010 | 0.003 | 0.960 |
Esophageal varices (yes vs. no) | 1.233 | 0.267 | 1.629 | 0.202 |
Portal hypertension (yes vs. no) | 0.075 | 0.784 | 0.001 | 0.970 |
Macrovascular invasion (yes vs. no) | 0.363 | 0.547 | 1.123 | 0.289 |
ALT, U/L (≤ 40 vs. >) | 0.138 | 0.710 | 0.001 | 0.977 |
TB, µmol/L (≤ 20 vs. > 22) | 8.898 | 0.003 | 1.987 | 0.159 |
PT, second (≤ 16 vs. > 16) | 7.515 | 0.006 | 9.216 | 0.002 |
INR (≤ 1.2 vs. > 1.2) | 0.953 | 0.329 | 0.071 | 0.790 |
PIVKA-II, mAU/mL (≤ 40 vs. > 40) | 0.453 | 0.501 | 2.717 | 0.099 |
AFP, ng/ml (≤ 200 vs. > 200) | 10.878 | 0.001 | 6.077 | 0.014 |
